Iodine Products, Inc.  ·  Miami, Florida Est. Over 50 Years of Clinical Evidence 24×7 Consultation Available
An evidence-based resource on

Fibrocystic
Breast Disease

The most common benign breast condition in premenopausal women — and the one most quietly undertreated. Fifty years of peer-reviewed research point to a safe, simple, topical intervention that most women have never been offered.
◆ ◆ ◆

If you have been told your lumpy, tender, painful breasts are "just fibrocystic" and that there is nothing to be done — the published clinical record says otherwise. A 1,365-patient trial demonstrated that topical molecular iodine produced objective improvement in 65 to 74 percent of women. This site exists to make that evidence, and the product that delivers it, genuinely accessible.

Please choose the path that fits you
The Published Clinical Record

The evidence is stronger than most women or their doctors realize.

1,365
Women enrolled in the Ghent molecular iodine trial
65–74%
Showed objective and subjective improvement with molecular I₂
65%
Average improvement in fibrosis scores vs. 3% worsening on placebo
Increased breast cancer risk once ADH is identified on biopsy

Ghent W, Eskin B, et al. Canadian Journal of Surgery, 1993; 36:453–460.
Tomlinson-Hansen SE, Khan M, Cassaro S. StatPearls, NIH/NCBI, updated 2023.